

# Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

NCT05782270

---

Status	RECRUITING
Phase	Phase 4
Sponsor	China National Center for Cardiovascular Diseases
Enrollment	202 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.
- No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.
- Must be able to swallow tablets after the surgery.

### Exclusion (9)

- Patients with high bleeding risk (HAS-BLED  $\geq$  3);
- Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time;
- Emergency surgery;
- Serum creatinine  $>130\mu\text{mol/L}$ , or significant liver dysfunction (elevated ALT and/or AST);
- History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding;
- ... and 4 more (see full listing online)

## Locations (1 total)

---

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China